Holen Sie sich die Stockscreener-App
9.02
4.04%
-0.38
Schlusskurs vom Vortag:
$9.40
Offen:
$9.6
24-Stunden-Volumen:
491.89K
Relative Volume:
0.59
Marktkapitalisierung:
$204.42M
Einnahmen:
$146.07M
Nettoeinkommen (Verlust:
$-196.04M
KGV:
-0.5427
EPS:
-16.621
Netto-Cashflow:
$-75.37M
1W Leistung:
+0.22%
1M Leistung:
+26.33%
6M Leistung:
+41.60%
1J Leistung:
+103.15%
1-Tages-Spanne:
$8.90
$9.735
1-Wochen-Bereich:
$8.90
$10.22
52-Wochen-Spanne:
$3.6503
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Firmenname
Karyopharm Therapeutics Inc
Sektor
Branche
Telefon
617-658-0600
Adresse
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
9.02 | 204.42M | 146.07M | -196.04M | -75.37M | -16.62 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Rodman & Renshaw | Buy |
| 2026-02-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-13 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-01-19 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-07-23 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-05 | Bestätigt | Robert W. Baird | Outperform |
| 2019-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Bestätigt | BofA/Merrill | Underperform |
| 2019-02-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-05-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-04-02 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2016-09-08 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Hochstufung | Jefferies | Hold → Buy |
| 2016-08-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-28 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell - Seeking Alpha
H.C. Wainwright reiterates Karyopharm stock rating on trial data By Investing.com - Investing.com Canada
Karyopharm Therapeutics Inc (KPTI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Karyopharm Therapeutics Inc (KPTI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Karyopharm Therapeutics Inc (KPTI) Institutional Confidence - TradingKey
Karyopharm Therapeutics Inc (KPTI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Karyopharm Therapeutics Inc (KPTI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Karyopharm Therapeutics Inc (KPTI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Karyopharm Therapeutics Inc (KPTI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Karyopharm Therapeutics presents new Phase 3 SENTRY trial data in myelofibrosis at EHA - Traders Union
Karyopharm Therapeutics Inc (KPTI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
KPTI News | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI) - ChartMill
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress - TradingView
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress - GlobeNewswire Inc.
Karyopharm Therapeutics secures EHA Congress acclaim for late-breaking SENTRY trial update - Traders Union
Cantor Fitzgerald reiterates Overweight on Karyopharm stock - Investing.com UK
Cantor Fitzgerald reiterates Overweight on Karyopharm stock By Investing.com - Investing.com South Africa
How The Investment Story Is Evolving For Karyopharm Therapeutics (KPTI) - Yahoo Finance
T. Rowe Price (KPTI) files Schedule 13G/A showing 6.6% position - Stock Titan
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 - Karyopharm
Cancer expert joins Karyopharm's June 8 investor webcast - Stock Titan
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in MyelofibrosisSlideshow (NASDAQ:KPTI) 2026-06-02 - Seeking Alpha
KPTI: Karyopharm's Abstract Accepted for Presentation at Europea - GuruFocus
KPTI: Karyopharm Announces Positive Phase 3 SENTRY Trial Results - GuruFocus
KPTI: Selinexor plus ruxolitinib nearly doubled spleen response and improved survival in myelofibrosis - TradingView
Karyopharm reports phase 3 myelofibrosis trial results at ASCO - Investing.com UK
Karyopharm reports phase 3 myelofibrosis trial results at ASCO By Investing.com - Investing.com Nigeria
Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis - marketscreener.com
Karyopharm’s myelofibrosis trial selected for EHA presentation By Investing.com - Investing.com South Africa
Karyopharm’s myelofibrosis trial selected for EHA presentation - Investing.com UK
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 - Karyopharm
Cancer trial suggests spleen shrinkage may predict survival in myelofibrosis - Stock Titan
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology - Karyopharm
Karyopharm Therapeutics Presents Results from Phase 3 Sentry Trial of Selinexor Plus Ruxolitinib in Myelofibrosis - marketscreener.com
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Karyopharm Therapeutics (KPTI) to Discuss SENTRY Trial Results i - GuruFocus
Karyopharm to host call on phase 3 myelofibrosis trial results By Investing.com - Investing.com Australia
Karyopharm to host call on phase 3 myelofibrosis trial results - Investing.com
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation - Karyopharm
Myelofibrosis Phase 3 trial data to be detailed on June 2 call - Stock Titan
KPTI Q1 2026 Earnings: EPS Beats Estimates Despite Revenue Absence, Stock DipsQuarterly Profit Report - newsline.com
Karyopharm shares rise 10% after mixed Phase 3 SENTRY trial results - MSN
Karyopharm Therapeutics (KPTI) Holds Near $9.10 Amid Low-Volume ConsolidationPercent Below MA - newsline.com
Karyopharm (NASDAQ: KPTI) boosts share plans and grants CEO PSU awards - Stock Titan
Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference - Karyopharm
Karyopharm to Speak at 2026 Jefferies Global Healthcare Conference - Intellectia AI
Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):